PART 01: Executive summary • Highlights PART 02: Scope of the report • Market overview • Top-vendor offerings PART 03: Market research methodology • Research methodology • Economic indicators PART 04: Introduction • Key market highlights • Key buying criteria PART 05: Heparin: An overview • Mechanism of action (MOA) • Limitations of heparin use • Clinical uses of heparin • Branded drug profiles PART 06: Pipeline portfolio • LMW Heparin MMX • URG101 • Heparin • Heparin plus dexoyribonuclease (DNAse) • Heparin plus other inhaled drug PART 07: Market landscape • Global anticoagulant drugs market • Global heparin market • Five forces analysis PART 08: Heparin use in CPB surgery • CPB • Heparin use in CPB surgery • Global heparin market in CPB surgeries PART 09: Heparin API market • China: Heparin API market PART 10: Suppliers of crude heparin • FDA guidance for heparin suppliers • PART 11: Market segmentation by product type • UFH • LMWH • ULMWH PART 12: Market segmentation by ROA • IV injection/infusion • SC injection PART 13: Geographical segmentation • Global heparin market by geographical segmentation 2015-2020 • Heparin market in EMEA • Heparin market in Americas • Heparin market in APAC PART 14: Market drivers • Growing prevalence of diseases • Increase in supply chains of crude heparin • Reintroduction of bovine heparin by US FDA PART 15: Impact of drivers PART 16: Market challenges • Extensive use of generic products due to patent expirations • Risk of side-effects • Shortage of crude heparin • Threat of adulteration • Presence of well-established oral anticoagulants PART 17: Impact of drivers and challenges PART 18: Market trends • Expected exploitation of new therapeutic use • Strategic alliances • Increase in R&D • Entry of new heparin antidotes PART 19: Vendor landscape • Competitive scenario • Market analysis 2015 • Sanofi • Pfizer • Aspen • LEO Pharma • Other prominent vendors PART 20: Appendix • List of abbreviations PART 21: Explore Technavio List of Exhibits Exhibit 01: Product offerings Exhibit 02: Key buying criteria for heparin drugs Exhibit 03: Differences between porcine heparin and bovine heparin Exhibit 04: Process of blood coagulation Exhibit 05: Mechanism of action of heparin Exhibit 06: Pipeline portfolio: Heparin drugs Exhibit 07: Market share of global heparin market in global anticoagulant drugs market 2015 Exhibit 08: Global anticoagulant drugs market 2015-2020 ($ billions) Exhibit 09: Global heparin market 2015-2020 ($ billions) Exhibit 10: Five forces analysis Exhibit 11: Global heparin market in CPB surgeries 2015-2020 ($ millions) Exhibit 12: Process of crude heparin production in China Exhibit 13: Segmentation of global heparin market by product type 2015 Exhibit 14: Segmentation of global heparin market by ROA Exhibit 15: Segmentation of global heparin market based on geography 2015 Exhibit 16: Global heparin market revenue by geography 2015-2020 ($ billions) Exhibit 17: Global heparin market by geography 2015-2020 Exhibit 18: Heparin market in EMEA 2015-2020 ($ billions) Exhibit 19: Heparin market in Americas 2015-2020 ($ billions) Exhibit 20: Heparin market in APAC 2015-2020 ($ billions) Exhibit 21: Global heparin market: YoY growth and revenue based on geography 2015-2020 Exhibit 22: Impact of drivers Exhibit 23: Impact of drivers and challenges Exhibit 24: Sanofi: YoY revenue and growth rate of Lovenox 2013-2015 ($ billions) Exhibit 25: Geographical segmentation of Lovenox 2015 Exhibit 26: Sanofi: Key takeaways Exhibit 27: Pfizer: YoY revenue and growth rate of Fragmin 2013-2015 ($ millions) Exhibit 28: Geographical segmentation of Fragmin by revenue 2015 Exhibit 29: Pfizer: Key takeaways Exhibit 30: Aspen: Key takeaways Exhibit 31: LEO Pharma: Key takeaways

GlaxoSmithKline plc (GSK), Leo Pharma A/S, Pfizer Inc., Sanofi, Alchemi, Baxter, BMS, Boehringer Ingelheim, Celgene, Cosmo Pharmaceuticals, Dr.Reddy's Laboratories, Eisai, Fresenius, GSK, Hospira, Laboratorios Rovi Pharmaceuticals, Lee's Pharmaceutical, Momenta Pharmaceuticals, Mylan, Novartis, Ockham Biotech, Perospher, PolyMedix, Portola Pharmaceutical, ProStrakan Group, Sagent Pharmaceticals, Sigma Tau Pharmaceuticals, UCB, Urigen Pharmaceuticals.